Direct Stenting of TAXUS Liberté™-SR Stent for the Treatment of Patients With de Novo Coronary Artery Lesions

PHASE3CompletedINTERVENTIONAL
Enrollment

247

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

September 30, 2010

Conditions
Coronary Artery Disease
Interventions
DEVICE

TAXUS Liberté™-SR

Paclitaxel-Eluting Coronary Stent System

DEVICE

TAXUS Liberté™-SR

Paclitaxel-Eluting Coronary Stent System

Trial Locations (25)

1003

Mercy Angiography Unit, 98 Mountain Road, First Floor, Auckland

1023

Auckland City Hospital, Auckland

8001

Christchurch Hospital, Christchurch

20912

Washington Adventist Hospital, Takoma Park

27610

Wake Medical Center, Raleigh

32803

Florida Hospital, Orlando

37660

Wellmont Holston Valley Medical Center, Kingsport

46290

The Heart Center, Indianapolis

48439

Genesys Regional Medical Center, Grand Blanc

49770

Northern Michigan Hospital, Petoskey

55805

St. Mary's Duluth Clinic Regional Heart Center, Duluth

61108

St. Anthony's Medical Center, Rockford

62701

St. John's Hospital, Springfield

72205

University of Arkansas for Medical Sciences/Central Arkansas Veterans Healthcare Systems, Little Rock

73120

Oklahoma Foundation for Cardiovascular Research, Oklahoma City

80012

The Medical Center of Aurora, Aurora

95819

Mercy General Hospital, Sacramento

99204

Northwest Cardiovascular Research Institute, Spokane

119074

National University Hospital, Singapore

168752

National Heart Centre, Singapore

92103-8784

University of California San Diego Medical Center, San Diego

04102

Maine Medical Center, Portland

17033-0850

The Pennsylvania State University Milton S Hershey Medical Center, Hershey

Unknown

Dunedin Hospital, Dunedin

Shin Kong Memorial Hospital, Shih Lin Taipei

Sponsors
All Listed Sponsors
lead

Boston Scientific Corporation

INDUSTRY